Canada Approves Gen-Probe's Prostate Cancer Assay | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Gen-Probe and DiagnoCure said today that Gen-Probe has received a regulatory medical device license from Health Canada, the Canadian government's department responsible for national public health, for a molecular urine test that determines the need for repeat biopsies for prostate cancer.

Gen-Probe exclusively licensed the worldwide rights to the PCA3 gene, on which its Progensa PCA3 assay is based, from its commercial partner DiagnoCure in 2003.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.